{"id":1783,"date":"2019-09-19T11:25:21","date_gmt":"2019-09-19T09:25:21","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=1783"},"modified":"2025-05-21T14:46:58","modified_gmt":"2025-05-21T12:46:58","slug":"tgf-beta-and-cancer","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/cancer-area\/molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell\/tgf-beta-and-cancer\/","title":{"rendered":"TGF-beta and cancer"},"content":{"rendered":"\n

\n\t\tTGF-beta and cancer\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

The research group’s focus is on studying the dual role of transforming growth factor (TGF)-\u03b2 in regulating the initiation and progression of liver cancer, as well as deciphering the relevance of other signaling pathways that interact with it, particularly the epidermal growth factor (EGF). In recent years, we have made progress in studying the TGF-\u03b2 signaling pathway and have identified the production of reactive oxygen species (ROS) mediated by the NADPH oxidase family, particularly NOX4, as a key element in TGF-\u03b2 function.<\/p>\n

Currently, we are working on advancing in:<\/p>\n